Deciphering m<sup>6</sup>A methylation in monocyte-mediated cardiac fibrosis and monocyte-hitchhiked erythrocyte microvesicle biohybrid therapy

Li, Jiawen; Wei, Li; Hu, Kaifeng; He, Yunxiang; Gong, Guidong; Liu, Qisong; Zhang, Yue; Zhou, Kaiyu; Guo, Junling; Hua, Yimin; Tang, Jun; Li, Yifei

doi:10.7150/thno.95664

Theranostics

2024

DOI: 10.7150/thno.95664

|View full text |Cite

Deciphering m⁶A methylation in monocyte-mediated cardiac fibrosis and monocyte-hitchhiked erythrocyte microvesicle biohybrid therapy

Jiawen Li,

Li Wei,

Kaifeng Hu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Polyphenol‐Nanoengineered Monocyte Biohybrids for Targeted Cardiac Repair and Immunomodulation

Li,

Gong,

Zhang

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Myocardial infarction is one of the leading cause of cardiovascular death worldwide. Invasive interventional procedures and medications are applied to attenuate the attacks associated with ischemic heart disease by reestablishing blood flow and restoring oxygen supply. However, the overactivation of inflammatory responses and unsatisfactory drug delivery efficiency in the infarcted regions prohibit functional improvement. Here, a nanoengineered monocyte (MO)‐based biohybrid system, referred to as CTAs @MOs, for the heart‐targeted delivery of combinational therapeutic agents (CTAs) containing anti‐inflammatory IL‐10 and cardiomyogenic miR‐19a to overcome the limitation of malperfusion within the infarcted myocardium through a polyphenol‐mediated interfacial assembly, is reported. Systemic administration of CTAs@MOs bypasses extensive thoracotomy and intramyocardial administration risks, leading to infarcted heart‐specific accumulation and sustained release of therapeutic agents, enabling immunomodulation of the proinflammatory microenvironment and promoting cardiomyocyte proliferation in sequence. Moreover, CTAs@MOs, which serve as a cellular biohybrid‐based therapy, significantly improve cardiac function as evidenced by enhanced ejection fractions, increased fractional shortening, and diminished infarct sizes. This polyphenol nanoengineered biohybrid system represents a general and potent platform for the efficient treatment of cardiovascular disorders.

show abstract

Polyphenol‐Nanoengineered Monocyte Biohybrids for Targeted Cardiac Repair and Immunomodulation

Li,

Gong,

Zhang

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

m6A Ribonucleic Acid Methylation in Fibrotic Diseases of Visceral Organs

Dai,

Cheng,

Luo

et al. 2024

Small Science

View full text Add to dashboard Cite

Fibrosis is a pathological process characterized by the excessive deposition of extracellular matrix in the tissue's extracellular space, leading to structural injury and organ dysfunction, and even organ failure, posing a threat to human life. Despite mounting evidence suggesting that fibrosis is reversible, effective treatments for fibrotic diseases are lacking. Accumulating evidence has elucidated that ribonucleic acid (RNA) modifications have emerged as novel mechanisms regulating gene expression. N6‐methyladenosine (m6A) modification is a well‐known prevalent RNA posttranscriptional modification that participates in essential biological processes such as RNA splicing, translation, and degradation. It is tightly implicated in a wide range of cellular processes and various human diseases, particularly in organ fibrosis. The m6A modification is a dynamic and reversible process regulated by methylases, commonly known as “writers,” and demethylases referred to as “erasers,” while m6A modifications are recognized by “readers.” Accumulating evidence suggests that m6A modification on RNAs is tightly associated with fibrotic diseases of visceral organs including the lungs, heart, liver, and kidney. In this review, recent advances in the impact of m6A methylation of RNAs on visceral organ fibrosis are highlighted and the potential prospects for therapy in treating fibrotic diseases of visceral organs are discussed.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Deciphering m⁶A methylation in monocyte-mediated cardiac fibrosis and monocyte-hitchhiked erythrocyte microvesicle biohybrid therapy

Cited by 2 publications

References 49 publications

Polyphenol‐Nanoengineered Monocyte Biohybrids for Targeted Cardiac Repair and Immunomodulation

Polyphenol‐Nanoengineered Monocyte Biohybrids for Targeted Cardiac Repair and Immunomodulation

m6A Ribonucleic Acid Methylation in Fibrotic Diseases of Visceral Organs

Contact Info

Product

Resources

About

Deciphering m6A methylation in monocyte-mediated cardiac fibrosis and monocyte-hitchhiked erythrocyte microvesicle biohybrid therapy

Cited by 2 publications

References 49 publications

Polyphenol‐Nanoengineered Monocyte Biohybrids for Targeted Cardiac Repair and Immunomodulation

Polyphenol‐Nanoengineered Monocyte Biohybrids for Targeted Cardiac Repair and Immunomodulation

m6A Ribonucleic Acid Methylation in Fibrotic Diseases of Visceral Organs

Contact Info

Product

Resources

About

Deciphering m⁶A methylation in monocyte-mediated cardiac fibrosis and monocyte-hitchhiked erythrocyte microvesicle biohybrid therapy